LYELのROE（自己資本利益率）は？

Lyell Immunopharma IncのROEは-90.04%です。

LYELの配当利回りは？

Lyell Immunopharma Incの配当利回りは0.00%です。

LYELの品質スコア（Quality Score）は？

当社のAIはLYELの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

LYELは今が買い時ですか？

当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

LYELはどのセクターに属しますか？

Lyell Immunopharma IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

LYEL (NASDAQ) 株価分析 | LYELL IMMUNOPHARMA INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

LYEL AI Analysis Summary

Our AI summary for LYEL: Lyell Immunopharma Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -90.04%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LYEL

Lyell Immunopharma Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 85

USD 13.60

0.73 (5.67%) Day Change

Watchlist Portfolio Compare Chart

0.03

D/E

-90.0%

ROE

-70.3%

ROA

0.00%

Div Yield

LYELL IMMUNOPHARMA INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 13.60 Price 0.73 (5.67%) Day Change	NEWS SCORE: 85

LYEL, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Deepscope 分析

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	85
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	13.60
PBV / Sector	1.15 / 44,022.72 GREAT
Earning Per Share	-10.63

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	2.01 M GREAT
Average 1W Daily Value	2.10 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-794,858.06 / 98.24
NPM Average (%) / Sector	-460,040.25 / -1,697.63
NPM Change Average (%) / Sector	20,904.32 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-70.28 / 185,260.96
ROA Average (%) / Sector	-54.33 / 36,684.70
ROA Change Average (%) / Sector	46.53 / 422,221.66 GREAT
ROE (%) / Sector	-90.04 / 243,762.23
ROE Average (%) / Sector	-69.60 / 48,758.47
ROE Change Average (%) / Sector	54.49 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

登録情報

Analyze Date	2026-08-05 08:00:30
Symbol	LYEL
Name	LYELL IMMUNOPHARMA INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	24.50 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	315.37 / 9,586.08

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 201 Haskins Way, South San Francisco, CA, United States, 94080

Phone: 650 695 0677

Website: https://www.lyell.com

Employees: 161

Sector: Healthcare >> Biotechnology

Description: Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.